Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05313152 · ClinicalTrials.gov registry record · Phase 1
Study of TAVO103A in Healthy Volunteers
A Phase 1 study, sponsored by Tavotek Biotherapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 30
- Enrollment target
NCT05313152: Completed Phase 1 study, sponsored by Tavotek Biotherapeutics.
NCT05313152 is a Phase 1 study that has completed, run by Tavotek Biotherapeutics. The registered enrollment target is 30 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05313152, a Phase 1 study, has completed, sponsored by Tavotek Biotherapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 30 participants
- Enrollment target
Study Summary
This is a Phase 1, single ascending dose study designed to investigate TAVO103A, administered as an IV infusion up to 60 minutes in length to healthy adult subjects. This study is designed to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of TAVO103A.
Interventions
- OTHER Placebo
- DRUG TAVO103A
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2022-04-05 |
| Est. Completion | 2023-06-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05313152
The ClinicalTrials.gov registry entry for NCT05313152 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Tavotek Biotherapeutics, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT05313152 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05313152 about?
NCT05313152 is a clinical study titled "Study of TAVO103A in Healthy Volunteers". This is a Phase 1, single ascending dose study designed to investigate TAVO103A, administered as an IV infusion up to 60 minutes in length to healthy adult subjects. This study is designed to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of TAVO103A.
What is the current status of trial NCT05313152?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2022-04-05. Estimated completion is 2023-06-08.
What interventions are being tested in trial NCT05313152?
The interventions under investigation include: Placebo (OTHER), TAVO103A (DRUG).
Who is sponsoring clinical trial NCT05313152?
This trial is sponsored by Tavotek Biotherapeutics, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.